AR015759A1 - Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones - Google Patents

Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones

Info

Publication number
AR015759A1
AR015759A1 ARP990101636A ARP990101636A AR015759A1 AR 015759 A1 AR015759 A1 AR 015759A1 AR P990101636 A ARP990101636 A AR P990101636A AR P990101636 A ARP990101636 A AR P990101636A AR 015759 A1 AR015759 A1 AR 015759A1
Authority
AR
Argentina
Prior art keywords
aryl
alkoxy
amino
group
carboxyl
Prior art date
Application number
ARP990101636A
Other languages
English (en)
Original Assignee
Searle & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Searle & Co filed Critical Searle & Co
Publication of AR015759A1 publication Critical patent/AR015759A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81—Amides; Imides
    • C07D213/82—Amides; Imides in position 3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/0202—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -NH-X-X-C(=0)-, X being an optionally substituted carbon atom or a heteroatom, e.g. beta-amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Cardiology (AREA)
  • Biochemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Communicable Diseases (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Vascular Medicine (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente se relaciona con una clase de compuestos representados por la formula (I) donde el grupo (II) es un anillo heterocíclico monocíclico de 5-8miembros, insaturado optativamente que contiene de 1 a 4 heteroátomos, seleccionados del grupo formado por O, N o S, donde X1 se selecciona del grupo formadopor CH, CH2, N, NH, O y S; A es la formula (III) donde Y1 se selecciona del grupo formado por N-R2, O, y S; R2 se selecciona del grupo formado por H, alquilo,arilo, hidroxi, alcoxi, ciano, nitro, amino, alquenilo, alquinilo, amida, alquilcarbonilo, arilcarbonilo, alcoxicarbonilo, ariloxicarbonilo,haloalquilcarbonilo, haloalcoxicarbonilo, alquiltiocarbonilo, ariltiocarbonilo, aciloximetoxicarbonilo, alquilo sustituido optativamente con unoo mássustituyentes seleccionados entre alquilo inferior, halogeno, hidroxilo, haloalquilo, ciano, nitro, carboxilo, amino, alcoxi, arilo o arilo sustituidooptativamente con uno o más grupos halogeno, haloalquilo, alquilo inferior, alcoxi, ciano, alquilsulfonilo, alquiltio, nitro, carboxilo, amino, hidroxilo,ácido sulfonico, sulfonamida, arilo, arilo fusionado, heterociclos monocíclicos o heterociclos monocíclicos fusionados, arilo sustituido optativamente con unoo más sustituyentes seleccionados entre grupos halogeno, haloalquilo, hidroxi, alquilo inferior, alcoxi, metilendioxi, etilendioxi, ciano, nitro, alquiltio,alquilsulfonilo, ácido sulfonico, sulfonamida, derivados de carboxilo, amino, arilo, arilo fusionado, heterociclos monocíclicos y heterociclos monocíclicosfusionados, heterociclos monocíclicos y heterociclos monocíclicos sustituidos optativamente con uno o más sustituyentes seleccionados entre grupos halogeno,haloalquilo, alquilo inferior, alcoxi, amino, nitro, hidroxi, derivados de carboxilo, ciano, alquiltio, alquilsulfonilo, ácido sulfonico, sulfonamida, arilo oarilo fusionado; o R2 tomado junto con R7, forma un dinitrogeno de 4-12 miembros que contiene heterociclo sustituido optativamente con uno o más sustituyentesseleccionados del grupo formado por alquilo inferior, tioalquilo, alquilamino, hidroxi, ceto, alcoxi, halo, fenilo, amino, carboxilo o carboxiléster y fenilo
ARP990101636A 1998-04-10 1999-04-09 Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones AR015759A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US8139498P 1998-04-10 1998-04-10

Publications (1)

Publication Number Publication Date
AR015759A1 true AR015759A1 (es) 2001-05-16

Family

ID=22163868

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP990101636A AR015759A1 (es) 1998-04-10 1999-04-09 Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones

Country Status (17)

Country Link
EP (1) EP1070060A1 (es)
JP (1) JP2002511462A (es)
KR (1) KR20010042614A (es)
CN (1) CN1304406A (es)
AR (1) AR015759A1 (es)
AU (1) AU765294B2 (es)
BR (1) BR9910119A (es)
CA (1) CA2326665A1 (es)
CZ (1) CZ20003672A3 (es)
IL (1) IL138677A0 (es)
MY (1) MY133473A (es)
NO (1) NO20005084L (es)
NZ (1) NZ507292A (es)
PL (1) PL343406A1 (es)
RU (1) RU2215746C2 (es)
TW (1) TWI247008B (es)
WO (1) WO1999052896A1 (es)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6172256B1 (en) * 1998-03-04 2001-01-09 G.D. Searle & Co. Chiral-β-amino acid compounds and derivatives thereof
GB9805655D0 (en) 1998-03-16 1998-05-13 Celltech Therapeutics Ltd Chemical compounds
US6521626B1 (en) 1998-03-24 2003-02-18 Celltech R&D Limited Thiocarboxamide derivatives
GB9814414D0 (en) 1998-07-03 1998-09-02 Celltech Therapeutics Ltd Chemical compounds
GB9821061D0 (en) 1998-09-28 1998-11-18 Celltech Therapeutics Ltd Chemical compounds
GB9826174D0 (en) 1998-11-30 1999-01-20 Celltech Therapeutics Ltd Chemical compounds
JP2002533387A (ja) * 1998-12-23 2002-10-08 ジー．ディー．サール ＆ カンパニー 腫瘍治療の複合療法としてインテグリン拮抗物質と一つ以上の抗腫瘍剤を使用する方法
EP1156803A4 (en) 1999-02-09 2004-03-17 Bristol Myers Squibb Co FXA LACTAM INHIBITORS AND METHOD
TR200102959T2 (tr) * 1999-04-12 2002-04-22 Aventis Pharma Limited İntegrin antagonistleri olarak ikame edilmiş bisiklik heteroaril bileşikleri
GB9908355D0 (en) * 1999-04-12 1999-06-09 Rhone Poulenc Rorer Ltd Chemical compounds
SK15342001A3 (sk) * 1999-04-28 2002-06-04 Basf Aktiengesellschaft Antagonisty integrínového receptora
US6518283B1 (en) 1999-05-28 2003-02-11 Celltech R&D Limited Squaric acid derivatives
US6455539B2 (en) 1999-12-23 2002-09-24 Celltech R&D Limited Squaric acid derivates
JP2003531141A (ja) 2000-04-17 2003-10-21 セルテック アール アンド ディ リミテッド エナミン誘導体
US6545013B2 (en) 2000-05-30 2003-04-08 Celltech R&D Limited 2,7-naphthyridine derivatives
US6403608B1 (en) 2000-05-30 2002-06-11 Celltech R&D, Ltd. 3-Substituted isoquinolin-1-yl derivatives
EP1289959A1 (en) 2000-06-15 2003-03-12 Pharmacia Corporation Dihydrostilbene alkanoic acid derivatives useful as vitronectin antagonists
EP1305291A1 (en) 2000-08-02 2003-05-02 Celltech R&D Limited 3-substituted isoquinolin-1-yl derivatives
US6511973B2 (en) 2000-08-02 2003-01-28 Bristol-Myers Squibb Co. Lactam inhibitors of FXa and method
DE10204789A1 (de) * 2002-02-06 2003-08-14 Merck Patent Gmbh Inhibitoren des Integrins alpha¶v¶beta6
TW200307671A (en) 2002-05-24 2003-12-16 Elan Pharm Inc Heteroaryl compounds which inhibit leukocyte adhesion mediated by α 4 integrins
AU2003299600A1 (en) * 2002-12-20 2004-07-29 Pharmacia Corpration The r-isomer of beta amino acid compounds as integrin receptor antagonists derivatives
UA87854C2 (en) 2004-06-07 2009-08-25 Мерк Энд Ко., Инк. N-(2-benzyl)-2-phenylbutanamides as androgen receptor modulators
AU2008313733A1 (en) 2007-10-18 2009-04-23 Boehringer Ingelheim International Gmbh CGRP antagonists
EP2065381A1 (de) 2007-10-18 2009-06-03 Boehringer Ingelheim Pharma GmbH & Co. KG CGRP Antagonisten
US8829006B2 (en) 2007-11-22 2014-09-09 Boehringer Ingelheim International Gmbh Compounds
WO2009065922A2 (de) * 2007-11-22 2009-05-28 Boehringer Ingelheim International Gmbh Organische verbindungen
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
ES2647585T3 (es) 2012-07-18 2017-12-22 Saint Louis University Derivados de aminoácido beta como antagonistas de integrina
EP3148587B1 (en) 2014-05-30 2021-02-24 Pfizer Inc Carbonitrile derivatives as selective androgen receptor modulators
AU2016381336A1 (en) 2015-12-30 2018-06-28 Saint Louis University Meta-azacyclic amino benzoic acid derivatives as pan integrin antagonists
US10717736B2 (en) * 2016-11-08 2020-07-21 Bristol-Myers Squibb Company Pyrrole amides as alpha V integrin inhibitors
AU2021270095A1 (en) * 2020-05-14 2022-12-22 Ube Corporation 1, 4, 5, 6-tetrahydropyrimidine-2-amine derivative
WO2023275715A1 (en) 2021-06-30 2023-01-05 Pfizer Inc. Metabolites of selective androgen receptor modulators
WO2023085396A1 (ja) 2021-11-12 2023-05-19 Ｕｂｅ株式会社 アルポート症候群を治療または予防するための医薬組成物
CN115626912B (zh) * 2022-09-27 2024-03-26 中山大学 一种硫脲化合物及其制备方法与应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120859A (en) * 1989-09-22 1992-06-09 Genentech, Inc. Chimeric amino acid analogues
JPH11510814A (ja) * 1995-08-30 1999-09-21 ジー．ディー．サール アンド カンパニー インテグリンアンタゴニストとしてのメタ−グアニジン、尿素、チオ尿素またはアザ環状アミノ安息香酸誘導体
DE19629816A1 (de) * 1996-07-24 1998-01-29 Hoechst Ag Neue Cycloalkyl-Derivate als Inhibitoren der Knochenresorption und Vitronectinrezeptor-Antagonisten
WO1998008840A1 (en) * 1996-08-29 1998-03-05 Merck & Co., Inc. Integrin antagonists

Also Published As

Publication number Publication date
CN1304406A (zh) 2001-07-18
CA2326665A1 (en) 1999-10-21
WO1999052896A1 (en) 1999-10-21
CZ20003672A3 (cs) 2001-08-15
NO20005084L (no) 2000-11-27
BR9910119A (pt) 2001-10-09
PL343406A1 (en) 2001-08-13
NZ507292A (en) 2003-12-19
IL138677A0 (en) 2001-10-31
NO20005084D0 (no) 2000-10-09
RU2215746C2 (ru) 2003-11-10
JP2002511462A (ja) 2002-04-16
KR20010042614A (ko) 2001-05-25
EP1070060A1 (en) 2001-01-24
MY133473A (en) 2007-11-30
AU765294B2 (en) 2003-09-11
AU3449999A (en) 1999-11-01
TWI247008B (en) 2006-01-11

Similar Documents

Publication Publication Date Title
AR015759A1 (es) Compuesto derivado heterociclicos de glicil d-alanina, composicion farmaceutica que lo contiene y metodo para tratar afecciones
ECSP941085A (es) Derivados de amida, proceso para su preparacion y composicion farmaceuticas que los contiene
AR016429A1 (es) Compuesto derivado de acido hidroxamico como inhibidores de metaloproteasa de matriz (mmp), composiciones farmaceuticas y formulaciones veterinarias, usopara la preparacion de composiciones y formulaciones, compuesto intermediario, procedimiento de preparacion del compuesto.
ES2182535T3 (es) Derivados de benzo(b)tiepina-1,-dioxido, procedimiento para su preparacion, medicamentos que contienen estos compuestos y su utilizacion.
EA200600257A1 (ru) Производные триазолопиримидина в качестве ингибиторов киназы гликогенсинтазы-3
BRPI0810929B8 (pt) uso de um composto de fórmula 1
AR038863A1 (es) Uso de un inhibidor de garft y/o de aicarft y de un agente antitoxico para preparar un medicamento para destruir selectivamente celulas mtap-deficientes de un mamifero
AR055360A1 (es) Inhibidores macrociclicos del virus de la hepatitis c
RU2000128033A (ru) Гетероциклические производные глицил-бета-аланина в качестве антагонистов витронектина
PE20021005A1 (es) Quinazolinas como inhibidores de mmp-13
PE20050265A1 (es) Derivados de acido alquilarilo como inhibidores de diacilglicerol aciltransferasa tipo 1 (dgat-1)
EA200601852A1 (ru) Тетрагидрохинолиновые производные и способ их получения
PL348392A1 (en) Novel diphenylurea compounds, method of obtaining them and pharmacological preparations containing such compounds
WO2007149448A3 (en) Pyrazinones as cellular proliferation inhibitors
AR068376A1 (es) Amidas heterociclicas utiles para inhibir la via hedgehog.
ATE491704T1 (de) 4-ä2-(cycloalkylamino)pyrimidin-4-ylü- (phenyl)imidazolin-2-onderivate als inhibitoren der p38-map-kinase zur behandlung von entzündlichen krankheiten
EA200101181A1 (ru) Циклотиокарбаматные производные в качестве модуляторов рецептора прогестерона
PE20050160A1 (es) 3-aminopirrolidinas como inhibidores de la captacion de monoaminas
DK435583A (da) Fremgangsmaade til fremstilling af heterocykliske derivater af cyklobutan
AR026222A1 (es) Compuestos derivados de acido antranilico
AR017097A1 (es) Compuestos de 2-(3h)-oxazolona, utiles como inhibidores selectivos de cox-2; procedimiento para preparar dichos compuestos y composiciones farmaceuticasformuladas con dichos compuestos
EA201070197A1 (ru) Производные 1-оксо-изоиндолин-4-карбоксамидов и 1-оксо-1,2,3,4-тетрагидроизохинолин-5-карбоксамидов, способ их получения и применение в терапии
TR200103286T2 (tr) Projesteron reseptörü modülatörleri olarak siklokarbamat türevleri
SE8306764L (sv) Nya etendiamin- och guanidin-derivat
CO5031252A1 (es) Compuestos

Legal Events

Date Code Title Description
FB Suspension of granting procedure